3-(N-tert-butoxycarbonylamino)norbornane-2-carboxylic acid | 76198-37-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 3-(N-tert-butoxycarbonylamino)norbornane-2-carboxylic acid
• 英文别名: 3-{[(Tert-butoxy)carbonyl]amino}bicyclo[2.2.1]heptane-2-carboxylic acid；3-[(2-methylpropan-2-yl)oxycarbonylamino]bicyclo[2.2.1]heptane-2-carboxylic acid
• CAS: 76198-37-3
• 化学式: C₁₃H₂₁NO₄
• mdl: MFCD19382053
• 分子量: 255.314
• InChiKey: BWIMUIWFDXMFLE-UHFFFAOYSA-N

物化性质

• 沸点：
  414.1±24.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.846
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-aminonorbornane-2-carboxylic acid 、 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 在 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 3-(N-tert-butoxycarbonylamino)norbornane-2-carboxylic acid
  参考文献：
  名称：

  5-Fluorouracil derivatives, and their pharmaceutical compositions

  摘要：

  一种化合物的化学式为：##STR1##其中R是从诺伯尼尔、诺伯烯基、双环[2,2,2]-庚基和金刚烷基中选择的桥环脂环基，可选择地被来自较低烷基、羧基、较低烷氧羰基、烷基二氧基、N,N-双(较低)烷基氨基甲酰、氨基、较低烷氧羰胺基和卤素的至少一种取代基取代。该化合物可用于治疗人类和动物的癌症。

  公开号：

  US04349552A1

文献信息

• FUSED QUINOLINE DERIVATIVE AND USE THEREOF
  申请人：Kajino Masahiro

  公开号：US20090275568A1

  公开（公告）日：2009-11-05

  The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I) wherein R 1 is a hydrogen atom and the like; R 2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R 3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R 4 and R 5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R 6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R 7 , R 8 , R 9 and R 10 are the same or different and each is a hydrogen atom, halogen and the like; or R 7 and R 8 , R 8 and R 9 , and R 9 and R 10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5; represents unsubstituted (i.e., absence) or a single bond; and represents a single bond or a double bond, or a salt thereof, and the like.

  本发明旨在提供一种具有神经激肽2（NK2）受体拮抗作用的喹啉衍生物，涉及一种由式（I）表示的化合物，其中R1是氢原子等；R2是氢原子，烃基可选地具有取代基等；R3是未取代的（即不存在），氢原子等；R4和R5相同或不同，每个都是氢原子，烃基可选地具有取代基等；R6是（环状基团可选地具有取代基）-羰基等；R7，R8，R9和R10相同或不同，每个都是氢原子，卤素等；或R7和R8，R8和R9，以及R9和R10可以与相邻碳原子一起形成环；n是1到5的整数；表示未取代（即不存在）或单键；表示单键或双键，或其盐等。
• [EN] 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE<br/>[FR] DÉRIVÉS D'ACIDE 4-(2-FLUORO-4-MÉTHOXY-5-3-(((1-MÉTHYLCYCLOBUTYLE)MÉTHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL) CARBAMOYL)PHÉNOXY)-1-MÉTHYLCYCLOHEXANE-1-CARBOXYLIQUE ET COMPOSÉS SIMILAIRES COMME MODULATEURS DE RXFP1 POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
  申请人：ASTRAZENECA AB

  公开号：WO2022122773A1

  公开（公告）日：2022-06-16

  The present invention relates to 4-(2-Fluoro-4-methoxy-5-3-(((l- methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl) carbamoyl)phenoxy)-l-methylcyclohexane-l-carboxylic acid derivatives and similar compounds of formula (I) as RXFP1 modulators for the treatment of heart failure, heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, heart failure with reduced ejection fraction, chronic kidney disease and acute kidney injury. The present invention also relates to crystalline forms of such compounds. An exemplary compound is e.g. (A).

  本发明涉及4-(2-氟-4-甲氧基-5-3-(((1-甲基环丁基)甲基)氨基)双环[2.2.1]庚烷-2-基)氨基苯氧基)-1-甲基环己烷-1-羧酸衍生物及类似化合物，其为RXFP1调节剂，用于治疗心力衰竭、保留射血分数的心力衰竭、中等射血分数的心力衰竭、降低射血分数的心力衰竭、慢性肾脏病和急性肾损伤。本发明还涉及这种化合物的晶体形式。一个示例化合物是例如(A)。
• 5-Fluorouracil derivatives, preparation thereof and their pharmaceutical compositions
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0010941A1

  公开（公告）日：1980-05-14

  The present invention provides compounds of the general formula:- wherein R is an optionally substituted bridged alicyclic radical or a substituted lower alkyl radical, the substituent being an optionally substituted bridged alicyclic group, an amino, protected amino, lower alkoxy, acyl, lower alkylthio, cyano(lower)alkylthio, arylthio or optionally substituted heterocyclic radical or a carboxy and esterified carboxy group, with the proviso, that when the substituent is a carboxy or esterified carboxy group then the lower alkyl radical contains 3 to 6 carbon atoms; or an unsubstituted or substituted lower alkenyl radical, the substituent being an optionally substituted bridged alicyclic group, an optionally substituted aryl radical or an optionally substituted heterocyclic radical; or a halophenyl radical; or an optionally substituted heterocyclic radical. 'The present invention also provides processes for the preparation of these compounds and pharmaceutical composition containing them. Furthermore, the present invention is concerned with a method of treating cancer which comprises administering these compounds to mammals suffering from cancer.

  本发明提供通式为：- 的化合物。 其中 R 是任选取代的桥式脂环基或取代的低级烷基，取代基是任选取代的桥式脂环基、氨基、保护氨基、低级烷氧基、酰基、低级烷硫基、氰基（低级）烷硫基、芳硫基或任选取代的杂环基或羧基和酯化羧基，但条件是当取代基是羧基或酯化羧基时，低级烷基含有 3 至 6 个碳原子；或未取代或取代的低级烯基，取代基为任选取代的桥式脂环基、任选取代的芳基或任选取代的杂环基；或卤代苯基；或任选取代的杂环基。 '本发明还提供了制备这些化合物和含有这些化合物的药物组合物的工艺。此外，本发明还涉及一种治疗癌症的方法，该方法包括对患有癌症的哺乳动物施用这些化合物。
• US4349552A
  申请人：——

  公开号：US4349552A

  公开（公告）日：1982-09-14